What is HC Wainwright's Estimate for Kamada Q1 Earnings?

Kamada Ltd. (NASDAQ:KMDA - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for shares of Kamada in a report issued on Thursday, March 6th. HC Wainwright analyst A. Fein anticipates that the biotechnology company will earn $0.07 per share for the quarter. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada's Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.11 EPS and FY2029 earnings at $0.80 EPS.

Kamada Price Performance

Shares of KMDA stock traded up $0.04 during trading hours on Friday, reaching $7.12. 175,717 shares of the company were exchanged, compared to its average volume of 260,785. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.15. The stock's fifty day moving average is $7.13 and its two-hundred day moving average is $6.17. The company has a market cap of $409.26 million, a price-to-earnings ratio of 25.43, a P/E/G ratio of 0.97 and a beta of 0.97.

Institutional Investors Weigh In On Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in KMDA. Aristides Capital LLC boosted its holdings in Kamada by 12.1% in the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after acquiring an additional 6,850 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. NewEdge Advisors LLC grew its position in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after buying an additional 8,260 shares during the period. Plato Investment Management Ltd bought a new stake in shares of Kamada during the third quarter worth approximately $117,000. Finally, Public Employees Retirement System of Ohio acquired a new position in Kamada in the third quarter valued at approximately $77,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Kamada Announces Dividend

The company also recently disclosed a dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be given a $0.20 dividend. The ex-dividend date of this dividend is Monday, March 17th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.